Obesity is commonly defined as having too much body mass. A body mass index (BMI) of 30 or higher is the usual benchmark for obesity in adults. Anti-obesity drugs are medications, which are used to reduce body weight by lowering cholesterol levels in the body. These drugs affect the human body's basic functions by modifying appetite or eating calories. Anti-obesity drugs are commonly used for the treatment of obesity. The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved several anti-obesity drugs to treat obesity.
Increasing obese population and related chronic diseases, increase in concern of being overweight or obese, increase in demand for anti-obesity drugs, increase in research and development, and the outbreak of COVID-19 are major factors expected to drive the growth of the global anti-obesity drug market during the forecast period. For instance, in June 2021, the U.S. FDA approved Semaglutide 2.4 mg for chronic weight management in adults with obesity and/or overweight with at least one weight-related condition (such as high blood pressure or cholesterol, or T2D) for use in addition to a reduced-calorie diet and increased physical activity.
Moreover, in January 2021, Novartis, a global healthcare company, announced the results of its Phase II trial of an investigational product drug called Bimagrumab. The drug has shown potential for the indication of obesity. The drug is currently being studied in the Novartis pipeline.
- This report provides in-depth analysis of the global Anti-Obesity Drug Market, and provides market size (USD Mn) and Compound Annual Growth Rate (CAGR%) for the forecast period 2025-2032, considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global Anti-Obesity Drug Market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study are VIVUS Inc., Pfizer Inc., Novo Nordisk, Bayer AG, F Hoffmann-La Roche, Glaxosmithkline, Arena Pharmaceuticals, Eisai Co. Ltd., Takeda Pharmaceutical Company, and Nalpropion Pharmaceuticals Inc., among others.
- Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global anti-obesity drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global nti-Obesity Drug Market
-
- Prescription Drugs
- Over-the-Counter (OTC) Drugs
-
- GLP-1 Receptor Agonists
- Semaglutide
- Liraglutide
- Tirzepatide
- MC4R (Melanocortin-4 Receptor) Agonists
- Lipase Inhibitors
- Noradrenergic & Serotonergic Drugs
- Phentermine
- Diethylpropion
- Phendimetrazine
- Combination Therapies
- Phentermine/Topiramate
- Naltrexone/Bupropion
- Others
- Sodium-Glucose Co-Transporter-2 (SGLT-2) Inhibitors
- Empagliflozin
- Canagliflozin
- Bile Acid Sequestrants
- Amylin Analogs
- Others (Late Phase Drugs, etc.)
-
- Oral
- Parenteral
- Others (Transdermal)
-
-
-
- Adult
- Geriatric
- Pediatric
-
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
-
- North America
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
-
- Novo Nordisk
- GlaxoSmithKline
- AstraZeneca
- Pfizer
- Merck & Co.
- Sanofi
- Amgen
- Eli Lilly and Company
- Johnson & Johnson
- Takeda Pharmaceutical Company
- Abbott Laboratories
- Orexigen Therapeutics
- Zafgen
- Rhythm Pharmaceuticals
- Currax Pharmaceuticals
